Literature DB >> 25691635

Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.

Emi Takashita1, Maki Kiso2, Seiichiro Fujisaki1, Masaru Yokoyama3, Kazuya Nakamura1, Masayuki Shirakura1, Hironori Sato3, Takato Odagiri1, Yoshihiro Kawaoka4, Masato Tashiro5.   

Abstract

Between September 2013 and July 2014, 2,482 influenza 2009 pandemic A(H1N1) [A(H1N1)pdm09] viruses were screened in Japan for the H275Y substitution in their neuraminidase (NA) protein, which confers cross-resistance to oseltamivir and peramivir. We found that a large cluster of the H275Y mutant virus was present prior to the main influenza season in Sapporo /: Hokkaido, with the detection rate for this mutant virus reaching 29% in this area. Phylogenetic analysis suggested the clonal expansion of a single mutant virus in Sapporo /: Hokkaido. To understand the reason for this large cluster, we examined the in vitro and in vivo properties of the mutant virus. We found that it grew well in cell culture, with growth comparable to that of the wild-type virus. The cluster virus also replicated well in the upper respiratory tract of ferrets and was transmitted efficiently between ferrets by way of respiratory droplets. Almost all recently circulating A(H1N1)pdm09 viruses, including the cluster virus, possessed two substitutions in NA, V241I and N369K, which are known to increase replication and transmission fitness. A structural analysis of NA predicted that a third substitution (N386K) in the NA of the cluster virus destabilized the mutant NA structure in the presence of the V241I and N369K substitutions. Our results suggest that the cluster virus retained viral fitness to spread among humans and, accordingly, caused the large cluster in Sapporo/Hokkaido. However, the mutant NA structure was less stable than that of the wild-type virus. Therefore, once the wild-type virus began to circulate in the community, the mutant virus could not compete and faded out.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25691635      PMCID: PMC4394804          DOI: 10.1128/AAC.04836-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.

Authors:  Nicole M Bouvier; Saad Rahmat; Natalie Pica
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses.

Authors:  Teridah Ernala Ginting; Kyoko Shinya; Yukihiro Kyan; Akiko Makino; Naomi Matsumoto; Satoko Kaneda; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe.

Authors:  A Lackenby; O Hungnes; S G Dudman; A Meijer; W J Paget; A J Hay; M C Zambon
Journal:  Euro Surveill       Date:  2008-01-31

4.  Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.

Authors:  Masato Tashiro; Jennifer L McKimm-Breschkin; Takehiko Saito; Alexander Klimov; Catherine Macken; Maria Zambon; Frederick G Hayden
Journal:  Antivir Ther       Date:  2009

5.  Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.

Authors:  Marie-Anne Rameix-Welti; Sandie Munier; Sebastien Le Gal; Frederique Cuvelier; Fabrice Agou; Vincent Enouf; Nadia Naffakh; Sylvie van der Werf
Journal:  Antivir Ther       Date:  2011

6.  Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.

Authors:  Jesse D Bloom; Lizhi Ian Gong; David Baltimore
Journal:  Science       Date:  2010-06-04       Impact factor: 47.728

7.  Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.

Authors:  Shuji Hatakeyama; Yuko Sakai-Tagawa; Maki Kiso; Hideo Goto; Chiharu Kawakami; Keiko Mitamura; Norio Sugaya; Yasuo Suzuki; Yoshihiro Kawaoka
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

8.  Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan.

Authors:  Makoto Ujike; Kozue Shimabukuro; Kiku Mochizuki; Masatsugu Obuchi; Tsutomu Kageyama; Masayuki Shirakura; Noriko Kishida; Kazuyo Yamashita; Hiroshi Horikawa; Yumiko Kato; Nobuyuki Fujita; Masato Tashiro; Takato Odagiri
Journal:  Emerg Infect Dis       Date:  2010-06       Impact factor: 6.883

9.  Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses.

Authors:  Yacine Abed; Andrés Pizzorno; Xavier Bouhy; Guy Boivin
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

10.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses.

Authors:  Yasushi Itoh; Kyoko Shinya; Maki Kiso; Tokiko Watanabe; Yoshihiro Sakoda; Masato Hatta; Yukiko Muramoto; Daisuke Tamura; Yuko Sakai-Tagawa; Takeshi Noda; Saori Sakabe; Masaki Imai; Yasuko Hatta; Shinji Watanabe; Chengjun Li; Shinya Yamada; Ken Fujii; Shin Murakami; Hirotaka Imai; Satoshi Kakugawa; Mutsumi Ito; Ryo Takano; Kiyoko Iwatsuki-Horimoto; Masayuki Shimojima; Taisuke Horimoto; Hideo Goto; Kei Takahashi; Akiko Makino; Hirohito Ishigaki; Misako Nakayama; Masatoshi Okamatsu; Kazuo Takahashi; David Warshauer; Peter A Shult; Reiko Saito; Hiroshi Suzuki; Yousuke Furuta; Makoto Yamashita; Keiko Mitamura; Kunio Nakano; Morio Nakamura; Rebecca Brockman-Schneider; Hiroshi Mitamura; Masahiko Yamazaki; Norio Sugaya; M Suresh; Makoto Ozawa; Gabriele Neumann; James Gern; Hiroshi Kida; Kazumasa Ogasawara; Yoshihiro Kawaoka
Journal:  Nature       Date:  2009-08-20       Impact factor: 49.962

View more
  31 in total

1.  Data-driven interdisciplinary mathematical modelling quantitatively unveils competition dynamics of co-circulating influenza strains.

Authors:  Bin-Shenq Ho; Kun-Mao Chao
Journal:  J Transl Med       Date:  2017-07-28       Impact factor: 5.531

2.  Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.

Authors:  Lianlian Jiang; Giovanna Fantoni; Laura Couzens; Jin Gao; Ewan Plant; Zhiping Ye; Maryna C Eichelberger; Hongquan Wan
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

3.  Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

Authors:  Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee
Journal:  Antiviral Res       Date:  2017-11-21       Impact factor: 5.970

4.  C646, a Novel p300/CREB-Binding Protein-Specific Inhibitor of Histone Acetyltransferase, Attenuates Influenza A Virus Infection.

Authors:  Dongming Zhao; Satoshi Fukuyama; Yuko Sakai-Tagawa; Emi Takashita; Jason E Shoemaker; Yoshihiro Kawaoka
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

5.  Destabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategy.

Authors:  Usama Ashraf; Laura Tengo; Laurent Le Corre; Guillaume Fournier; Patricia Busca; Andrew A McCarthy; Marie-Anne Rameix-Welti; Christine Gravier-Pelletier; Rob W H Ruigrok; Yves Jacob; Pierre-Olivier Vidalain; Nicolas Pietrancosta; Thibaut Crépin; Nadia Naffakh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-10       Impact factor: 11.205

6.  Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study.

Authors:  Kathy Leung; Marc Lipsitch; Kwok Yung Yuen; Joseph T Wu
Journal:  Lancet Infect Dis       Date:  2016-12-01       Impact factor: 25.071

Review 7.  Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance.

Authors:  Julianna Han; Jasmine Perez; Adam Schafer; Han Cheng; Norton Peet; Lijun Rong; Balaji Manicassamy
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

8.  Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.

Authors:  Leo Y Lee; Jie Zhou; Paulina Koszalka; Rebecca Frise; Rubaiyea Farrukee; Keiko Baba; Shahjahan Miah; Takao Shishido; Monica Galiano; Takashi Hashimoto; Shinya Omoto; Takeki Uehara; Edin J Mifsud; Neil Collinson; Klaus Kuhlbusch; Barry Clinch; Steffen Wildum; Wendy S Barclay; Aeron C Hurt
Journal:  PLoS Pathog       Date:  2021-05-06       Impact factor: 6.823

Review 9.  Understanding the Impact of Resistance to Influenza Antivirals.

Authors:  Edward C Holmes; Aeron C Hurt; Zuzana Dobbie; Barry Clinch; John S Oxford; Pedro A Piedra
Journal:  Clin Microbiol Rev       Date:  2021-02-10       Impact factor: 26.132

Review 10.  Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.

Authors:  Michael G Ison; Frederick G Hayden; Alan J Hay; Larisa V Gubareva; Elena A Govorkova; Emi Takashita; Jennifer L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2021-08-04       Impact factor: 10.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.